SCHEMBL932722

SCHEMBL932722

COCCOCCS(=O)(=O)O

nearest known ligand 0.44

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
CA2 P00918 1/20 0.44
PTGS1 P23219 1/20 0.40
PDE4A P27815 1/20 0.40
LMNA P02545 1/20 0.35
SLC6A6 P31641 1/20 0.35
CYP2C19 P33261 1/20 0.35
BLM P54132 1/20 0.35
APP P05067 1/20 0.32
EPHX2 P34913 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24983142 1.00 CA2 (0.44) CA2PTGS1PDE4ALMNASLC6A6
SCHEMBL16941472 1.00 CA2 (0.44) CA2PTGS1PDE4ALMNASLC6A6
SCHEMBL7869938 0.87 PTGS1 (0.50) CA2PTGS1PDE4ALMNASLC6A6
SCHEMBL9813894 0.86 CA2 (0.41) CA2PTGS1PDE4ALMNASLC6A6
SCHEMBL3469908 0.86 CA2 (0.41) CA2PTGS1PDE4ALMNASLC6A6
SCHEMBL496774 0.85
Sulfuric Acid SCHEMBL8643620 0.85 CA2 (0.50) CA2EPHX2
SCHEMBL14114300 0.85 CA2 (0.40) CA2PTGS1PDE4ALMNASLC6A6
SCHEMBL14195598 0.85 CA2 (0.40) CA2PTGS1PDE4ALMNASLC6A6
SCHEMBL418534 0.84 PTGS1 (0.53) CA2PTGS1PDE4ALMNASLC6A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120264907-A1 PREPARATION OF POLYAMIDES INVISTA NORTH AMERICA S.A.R.L. (US) 2012-10-18 US claimed
EP-2451863-A1 PREPARATION OF POLYAMIDES Invista Technologies S.A R.L. (CH) 2012-05-16 EP claimed
WO-2011004138-A1 PREPARATION OF POLYAMIDES INVISTA TECHNOLOGIES S.A.R.L. (CH) 2011-01-13 WO claimed
EP-2640686-B1 NITROUS OXIDE-CONTAINING IONIC LIQUIDS AS CHEMICAL REAGENTS INVISTA TECH SARL (CH) 2014-12-24 EP disclosed
US-8772438-B2 Preparation of polyamides Invista North America S.är.l. (US) 2014-07-08 US disclosed
US-20130299738-A1 NITROUS OXIDE-CONTAINING IONIC LIQUIDS AS CHEMICAL REAGENTS INVISTA NORTH AMERICA S.A.R.L. (US) 2013-11-14 US disclosed
EP-2640686-A2 NITROUS OXIDE-CONTAINING IONIC LIQUIDS AS CHEMICAL REAGENTS Invista Technologies S.A R.L. (CH) 2013-09-25 EP disclosed
EP-2456807-B1 SYNTHESIS METHOD USING IONIC LIQUIDS INVISTA TECH SARL (CH) 2013-07-17 EP disclosed
US-20120264907-A1 PREPARATION OF POLYAMIDES INVISTA NORTH AMERICA S.A.R.L. (US) 2012-10-18 US disclosed
CN-101505844-B Extraction process INVISTA TECH SARL 2012-07-11 CN disclosed
EP-2456807-A2 SYNTHESIS METHOD USING IONIC LIQUIDS Invista Technologies S.A R.L. (CH) 2012-05-30 EP disclosed
WO-2012066296-A2 NITROUS OXIDE-CONTAINING IONIC LIQUIDS AS CHEMICAL REAGENTS INVISTA TECHNOLOGIES S.A.R. L. (CH) 2012-05-24 WO disclosed
EP-2451863-A1 PREPARATION OF POLYAMIDES Invista Technologies S.A R.L. (CH) 2012-05-16 EP disclosed
WO-2011010116-A2 SYNTHESIS METHOD USING IONIC LIQUIDS INVISTA TECHNOLOGIES S.À.R.L. (CH) 2011-01-27 WO disclosed
WO-2011004138-A1 PREPARATION OF POLYAMIDES INVISTA TECHNOLOGIES S.A.R.L. (CH) 2011-01-13 WO disclosed
CN-101505844-A Extraction process INVISTA TECH SARL (CH) 2009-08-12 CN disclosed
EP-2051788-A1 EXTRACTION PROCESS USING AN IONIC LIQUID Invista Technologies S.à.r.l. (CH) 2009-04-29 EP disclosed
US-7442841-B2 Extraction process INVISTA NORTH AMERICA S.A R.L. (US) 2008-10-28 US disclosed
US-20080051609-A1 EXTRACTION PROCESS INVISTA NORTH AMERICA S.A.R.L. (US) 2008-02-28 US disclosed
WO-2008022233-A1 EXTRACTION PROCESS USING AN IONIC LIQUID INVISTA TECHNOLOGIES S.A.R.L. (CH) 2008-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080051609-A1 EXTRACTION PROCESS ADH1C, ADH1A, ADH5 CA2 4188/4885PTGS1 4085/4885PDE4A 4077/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.